Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Aroa Biosurgery Ltd

Healthcare AU ARX

0.66AUD
-0.015(2.22%)

Last update at 2026-06-04T05:59:00Z

Day Range

0.650.68
LowHigh

52 Week Range

0.460.80
LowHigh

Fundamentals

  • Previous Close 0.68
  • Market Cap235.79M
  • Volume131853
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA3.82M
  • Revenue TTM90.40M
  • Revenue Per Share TTM0.26
  • Gross Profit TTM 76.90M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Income before tax 3.85M -2.95347M -9.56390M -0.35945M -7.67822M
Minority interest - - - - -
Net income 4.16M -3.46510M -9.74827M -0.37068M -7.79440M
Selling general administrative - 60.93M 0.60M 47.71M 28.54M
Selling and marketing expenses - 60.93M 57.01M 44.66M 28.54M
Gross profit 79.63M 65.99M 54.10M 50.06M 28.17M
Reconciled depreciation - 4.49M 4.03M 3.59M 2.91M
Ebit 4.36M -1.84569M -9.78771M -0.35383M -6.98113M
Ebitda 9.03M 2.65M -6.78379M 3.24M -4.07101M
Depreciation and amortization 4.67M 4.49M 3.00M 3.59M 2.91M
Non operating income net other - - - - -
Operating income 4.36M -8.12795M -9.78771M -0.35383M -6.98113M
Other operating expenses 87.92M 85.10M 78.70M 67.44M 47.93M
Interest expense 0.42M 0.44M 1.16M 0.00562M 0.70M
Tax provision - 0.51M 0.18M 0.01M 0.12M
Interest income - 0.96M 1.65M 2.73M 0.37M
Net interest income - -0.57797M 0.04M 0.87M -0.69709M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.31012M 0.51M 0.18M 0.01M 0.12M
Total revenue 92.28M 76.97M 63.36M 59.31M 36.88M
Total operating expenses 75.27M 74.12M 69.45M 58.19M 39.22M
Cost of revenue 12.66M 10.98M 9.26M 9.25M 8.72M
Total other income expense net -0.51361M 5.17M 0.22M 3.30M 1.16M
Discontinued operations - - - - -
Net income from continuing ops - -3.46510M -9.74956M -0.37068M -7.79440M
Net income applicable to common shares - -3.81300M -10.62800M -0.39600M -8.38600M
Preferred stock and other adjustments - - - - -
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total assets 100.48M 98.94M 101.82M 109.07M 104.71M
Intangible assets 11.56M 12.33M - 11.31M 10.90M
Earning assets - - - - -
Other current assets 2.91M 19.47M 1.66M 10.36M 1.23M
Total liab 17.74M 14.35M 14.78M 13.69M 11.30M
Total stockholder equity 82.74M 84.59M 87.04M 95.38M 93.40M
Deferred long term liab - - - 1.33M -
Other current liab 7.38M 6.83M 6.24M 5.10M 4.45M
Common stock 122.53M 133.44M 134.59M 137.13M 135.47M
Capital stock - 133.44M - 137.13M 135.47M
Retained earnings -44.81976M -58.21338M -56.98378M -48.22990M -47.52115M
Other liab - - - - 0.16M
Good will 4.61M 5.03M 5.08M 5.18M 5.15M
Other assets - - - 0.13M 0.15M
Cash 17.54M 7.26M 10.56M 8.93M 5.73M
Cash and equivalents - - - - -
Total current liabilities 13.50M 9.36M 8.72M 7.41M 6.24M
Current deferred revenue - - 0.00000M - -
Net debt -12.23107M -1.43130M -3.74715M -2.27745M -0.26861M
Short term debt 1.23M 1.02M 0.92M 0.52M 0.55M
Short long term debt - - - - -
Short long term debt total 5.31M 5.83M 6.82M 6.65M 5.46M
Other stockholder equity - - 0.00000M 0.00000M 5.86M
Property plant equipment - - - 20.64M 15.36M
Total current assets 64.37M 61.95M 63.29M 73.14M 74.24M
Long term investments - - - - -
Net tangible assets - - - 85.60M 83.22M
Short term investments 5.06M 12.87M 17.15M 34.07M 47.62M
Net receivables 33.84M 14.84M 26.49M 13.41M 15.96M
Long term debt - - - - -
Inventory 5.01M 7.52M 7.43M 4.52M 3.70M
Accounts payable 4.88M 1.51M 1.57M 1.79M 1.24M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 5.03M 9.36M 9.44M 6.48M 5.45M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.05M 0.07M 13.08M 0.12M 0.14M
Deferred long term asset charges - - - - -
Non current assets total 36.12M 36.98M 38.53M 35.93M 30.46M
Capital lease obligations - 5.83M - 6.65M 5.46M
Long term debt total - - - 6.55M 5.29M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Investments - 0.27M 9.31M 6.79M -30.00000M
Change to liabilities - - - - 1.32M
Total cashflows from investing activities 3.80M 0.27M 9.31M 7.25M -34.87100M
Net borrowings - - - - -10.08900M
Total cash from financing activities -1.54882M -1.33860M -0.94841M -0.47178M 34.98M
Change to operating activities - - - - -1.33700M
Net income 4.16M -3.46510M -9.85176M -0.37068M -8.38600M
Change in cash 10.28M -3.20883M 1.82M 3.16M -8.56585M
Begin period cash flow 7.26M 10.47M 8.75M 5.77M 14.30M
End period cash flow 17.54M 7.26M 10.57M 8.93M 5.73M
Total cash from operating activities 9.37M -2.33188M -6.76453M -3.77200M -11.52200M
Issuance of capital stock - 0.00909M 0.18M 0.49M 46.77M
Depreciation 4.67M - 4.09M - 3.13M
Other cashflows from investing activities - -1.26318M -3.17753M 14.87M -30.00000M
Dividends paid - - - - -
Change to inventory 2.00M -0.15111M -3.03395M - -0.32300M
Change to account receivables -5.07211M -2.63165M 0.81M - -10.38800M
Sale purchase of stock - -1.34769M -1.12834M -0.95853M -2.05781M
Other cashflows from financing activities -1.61547M 0.92M -0.45135M 0.00000M -0.89506M
Change to netincome - - - - 4.32M
Capital expenditures 0.99M 3.36M 3.23M 7.12M 4.53M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.83528M -6.93188M -6.23071M 1.17M 0.14M
Stock based compensation - - 2.92M - -
Other non cash items 1.38M 4.60M 9.32M - -
Free cash flow 8.39M -5.69338M -9.99592M -7.12440M -4.52737M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ARX
Aroa Biosurgery Ltd		 -0.015 2.22% 0.66 - 83.33 2.61 2.93 2.54 55.55
COH
Cochlear Ltd		 - -% 95.10 18.48 18.62 2.72 3.31 2.76 11.44
4DX
4DMEDICAL Ltd		 0.13 3.43% 3.92 - - 340.72 37.59 355.67 -7.2899
AVR
Anteris Technologies Global Corp		 -1.01 7.77% 11.99 - - 630.02 3.17 326.80 -5.1986
PNV
Polynovo Ltd		 -0.005 0.47% 1.07 125.50 40.49 6.22 10.01 5.96 119.61

Reports Covered

Stock Research & News

View All

Profile

Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that delivers a bolus of biologically important ECM proteins to help kick start and sustain healing; and Symphony, a combination cellular and tissue product, indicated for the regeneration of functional tissue in complex wounds. The company also develops products for abdominal wall reconstruction, hernia repair, and breast reconstruction in North America and Europe. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.

Aroa Biosurgery Ltd

64 Richard Pearse Drive, Auckland, New Zealand, 2022

Key Executives

Name Title Year Born
Dr. Brian Ward Founder, CEO, MD & Exec. Director NA
Mr. James Agnew BCom, LLB CFO & Joint Company Sec. NA
Dr. Barnaby C.H. May Ph.D. Chief Scientific Officer NA
Ms. Tracy Weimar BA, MBA Company Sec. NA
Dr. Brian Ward Founder, CEO, MD & Executive Director NA
Mr. James Agnew BCom, LLB CFO & Joint Company Secretary NA
Mr. Scott Sherriff B.A., M.B.A. Chief Operating Officer NA
Ms. Neetha Alex-Kumar General Counsel NA
Mr. Frazer Murray Director of Global Marketing & Strategy NA
Ms. Yasmin Winchester B.Sc. Vice President of Quality, Regulatory & Sustainability NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions